<DOC>
	<DOC>NCT02928289</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and effectiveness of the Sight Sciences VISCO™360 Viscosurgical System in reducing intraocular pressure (IOP) in adult, pseudophakic subjects with open-angle glaucoma.</brief_summary>
	<brief_title>Randomized Study of the Safety and Effectiveness of the Sight Sciences VISCO™360 Viscosurgical System Versus SLT in Primary Open Angle Glaucoma (VISCO360 Study)</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<criteria>Diagnosed with primary openangle glaucoma (POAG) in the study eye. Pseudophakic with Posterior Chamber IOL (PCIOL) Able and willing to attend follow up visits for two years postoperative Able and willing to sign informed consent Phakia or aphakia Previous glaucoma procedure with or without an implantable glaucoma device (including incisional surgery, ALT, iridectomy/iridotomy, etc.) [Subjects with one prior SLT application (&gt;3 months prior to screening) or prior ECP (performed &gt; 12 months prior to screening) can be enrolled]. Use of more than 3 ocular hypotensive medications (combination medications count as 2 medications) Diagnosis of acute angle closure, traumatic, congenital, malignant, uveitic, pseudoexfoliative, pigmentary or neovascular glaucoma Abnormal angle anatomy as determined by gonioscopy (e.g. peripheral anterior synechiae, rubeosis or other angle abnormalities) Participation in any clinical trial ≤ 30 days prior to screening</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>